A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs

Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offer improved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs). However, the translation of these non-natural molecules into successful therapeutics can be hampered by...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Itzel Condado-Morales, Fabian Dingfelder, Isabel Waibel, Oliver M. Turnbull, Bhargav Patel, Zheng Cao, Jais Rose Bjelke, Susanne Nedergaard Grell, Anja Bennet, Alissa M. Hummer, Matthew I. J. Raybould, Charlotte M. Deane, Thomas Egebjerg, Nikolai Lorenzen, Paolo Arosio
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Taylor & Francis Group 2024-12-01
Ráidu:	mAbs
Fáttát:	Antibody bispecifics fragments developability aggregation Fragmentation
Liŋkkat:	https://www.tandfonline.com/doi/10.1080/19420862.2024.2403156
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!